Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating

What: Arcutis Biotherapeutics' stock has jumped to an RS Rating of **82**, indicating strong market leadership.
Why: The company's stock price has risen **+34.6%** in the past six months, outperforming the S&P 500.
Signal: The stock's RS Rating has surpassed its 80-day moving average, signaling continued market outperformance.
Target: Analysts predict Arcutis Biotherapeutics' stock price to reach **$120.50** in the next 12 months.
Risk: Investors should be aware of the stock's high volatility, with a beta of **1.23**, indicating above-average price swings.